https://pubmed.ncbi.nlm.nih.gov/34398413/ Transplant

Indian J Pediatr. 2021 Aug 16.
doi: 10.1007/s12098-021-03826-1. Online ahead of print.

Liver Transplantation: A Safe and Definitive Alternative to Lifelong Nitisinone for Tyrosinemia Type 1

Jagadeesh Menon 1, Naresh Shanmugam 2, Joseph J Valamparampil 1, Abdul Hakeem 3, Mukul Vij 4, Anil Jalan 5, Mettu Srinivas Reddy 3, Mohamed Rela 3 6

Abstract

Objectives: To report the experience of liver transplantation (LT) for tyrosinemia type 1 (TT-1).

Methods: Clinical data of children with TT-1 who underwent living donor LT between July 2009 and May 2020 were retrospectively analyzed. Data included pre-LT nitisinone therapy, graft type, post-LT complications, HCC incidence, and graft/patient survival.

Results: Nine children were diagnosed with TT-1 at a median age of 12 mo (6-54 mo). Nitisinone was started in 6 patients at a median age of 15 mo (6-42 mo), but all had frequent interruption of therapy due to logistics with drug procurement including its cost. Median age at transplantation was 5 y (2-11 y). Explant liver showed HCC in 5 patients (55% of total cohort). The graft and patient survival are 100% with median follow-up of 58 mo (24-84 mo).
Conclusion: LT is curative for TT-1 and excellent results can be obtained in experienced centers. This is especially favorable in countries with limited resources where the cost of medical therapy is highly prohibitive, with lifelong diet restrictions and unclear long-term risk of HCC.